Werewolf Therapeutics (NASDAQ:HOWL) Raised to “Hold” at Wall Street Zen

Werewolf Therapeutics (NASDAQ:HOWL) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other equities research analysts also recently weighed in on HOWL. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. HC Wainwright reduced their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Finally, Wedbush downgraded Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Friday, December 19th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $1.04 on Tuesday. The business’s 50 day moving average price is $0.73 and its 200-day moving average price is $1.00. Werewolf Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.38. The company has a market cap of $50.54 million, a price-to-earnings ratio of -0.76 and a beta of 0.54.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.14. Sell-side analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 58,980 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60. Following the sale, the director owned 2,309,869 shares of the company’s stock, valued at approximately $1,316,625.33. This trade represents a 2.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 253,298 shares of company stock worth $143,888. 23.60% of the stock is currently owned by company insiders.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently made changes to their positions in the business. Regal Investment Advisors LLC raised its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC raised its stake in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.